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The patient study was approved by the Institutional Review Boards of the University of 
Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation.  
The patient with S1P deficiency is currently 11.5 years of age. She was born following an 
uncomplicated pregnancy to her gravida 3, para 2 mother and father. Birth weight at term was 
2.07 kg, which was small for gestational age at birth. At birth, no obvious abnormalities were 
identified. Up to 6 months of age, her length and weight were at 5%, after which gain in weight 
and height slowed down considerably (see growth chart, Supplemental Table 1). At 2 years of 
age she had bilateral cataract extraction, identified a few months earlier. Attainment of gross 
motor milestones was delayed, but speech and cognitive development were normal. At age 3 
years, she was seen in a pediatric Endocrinology clinic and thought to have Russell-Silver 
syndrome, but no molecular testing was pursued. Human growth hormone replacement therapy 
was started but discontinued after 1 year due to limited response. She had elective bilateral 
inguinal hernia repair at age 3½ years. At age 6 years, she was referred to pediatric orthopedics 
for back pain. Other than the short stature, she was thought to have an unusual face. Short stature 
was again observed, and other skeletal findings were pectus carinatum, kyphosis, and waddling 
gait. Radiology done at that time revealed spondylo-epiphyseal dysplasia with associated 
kyphosis. She was referred to Medical Genetics. A SNP (single nucleotide polymorphism) array 
revealed a heterozygous duplication on chr19q13.42 (genomic coordinates: chr19:54,659,105-
55,909,948 x3, hg19), found to be maternally inherited, and therefore assessed as a likely 
harmless copy number variant. COL2A1 (MIM (Mendelian inheritance in man database number) 
120140) sequencing was performed and found to be normal. At age 8 years, she was found to 
have markedly elevated plasma levels of various lysosomal enzymes (β-galactosidase, β-
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mannosidase, α-mannosidase, β-glucuronidase, α-glucosaminidase, and β-hexosaminidase), 
which was confirmed on repeat testing, while urinary glycosaminoglycans were normal. 
Deficient activity of UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-
phosphotransferase (GlcNAc-phosphotransferase; EC 2.7.8.17) was suspected. However, Sanger 
sequencing revealed no predicted pathogenic variants in GNPTAB (MIM 607840) and GNPTG 
(MIM 607838). Through whole exome sequencing, bi-allelic variants in MBTPS1, which 
encodes site-1 protease (S1P), were identified. The paternal variant was a nucleotide duplication 
(NM_003791.3: c.285dupT) in exon 3, predicted to create a nonsense change (p.D96X) (Fig. 
1C). The maternal variant was a nucleotide substitution (NM_003791.3: c.1094A>G) in exon 9, 
predicted to result in a missense variant substituting aspartic acid for glycine (p.D365G). At age 
9 years, a complete metabolic panel (including alkaline phosphatase) was normal; serum calcium 
was also normal, and parathyroid hormone was intact. At age 10 years, complete blood count 
was normal, and biochemical studies done as part of a bone health evaluation revealed normal 
bone specific alkaline phosphatase (56.4 µg/L, normal 47.9-150.8), elevated serum N-telopeptide -
(44.4, normal 6.2-19.0), elevated urine N-telopeptide/creatinine ratio (907, normal in Tanner 
Stage II Female 193-514), and elevated osteocalcin (58.0 ng/mL, normal in pre-menopausal 
women: 4.9-30.9). DXA scan revealed a z-score of -4.5 at total body less head (TBLH), and a z-
score of -3.3 at anterior-posterior (AP) spine. Even after correcting for her significant short 
stature, this is low. Vitamin D studies were normal. Echocardiogram at age 10½ years was 
normal. Radiographs done at 11½ years of age revealed stable complete anterolisthesis of 
vertebra L5 on S1 and bilateral shortening of the femoral necks with irregular and dysplastic 
appearance of the femoral and proximal tibial epiphyses. Fibula are gracile with valgus bowing. 
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She had dysmorphic facial features, with prominent forehead, prominent cheekbones, and large 
ears. 
For comparison, we also identified a patient with a mutation in MBTPS2 (the membrane-
bound transcription factor peptidase, site 2, S2P). S2P functions sequentially with S1P to cleave 
transmembrane transcription factors in response to ER stress or decreased sterol metabolites, 
important for regulating lipid biosynthesis and ER stress (1, 2). This patient has a hemizygous 
variant in MBTPS2 (c.1523 A>G, p.N508S, X-linked), inherited from his mother. This patient 
has short stature, developmental delay, seizures, photophobia, ichthyosis follicularis, and 
reduced body hair. The p.N508S variant in MBTPS2 has been reported previously, with 
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Supplemental Table 1. The growth chart of the S1P-deficient patient, which includes data 
on body length and weight of the patient (black lines) relative to the percentiles for healthy 




Supplemental Table 2. Comparison of the MBTPS1 mutation-caused syndrome with ML-
II/III, and MBTPS2 mutation-caused syndromes. ML-II/ III caused by genetic mutation in 
GNPTAB leads to skeletal dysplasia due to bone absorption and defective lysosomal functions. 
MBTPS1-encoded S1P and MBTPS2-encoded S2P are localized in the Golgi membrane. They 
sequentially cleave transcription factors to regulate ER stress or cholesterol synthesis. Although 
patients with pathogenic MBTPS2 variants have diverse clinical presentations (osteogenesis 














Affected protein S1P GPT S2P S2P  
Reduced cognition no yes yes no 
Short stature yes yes yes yes 
Cataract yes no no n/a  
Visual (photophobia) no no yes no 
Blue sclerae no no no yes 
Alopecia no no normal scalp hair, 
reduced eyebrow 




no no yes no 
Valvular cardiac 
defects 
no yes n/a n/a 
Inguinal hernia yes yes yes no 
Bone dysplasia yes yes yes yes 
Blood lipids yes (modest) no n/a n/a 
Elevated blood 
lysosome enzymes 




yes yes no no 
Affected organelle lysosome and ER lysosome ER ER 
Cellular defects defective functions 
of lysosome and ER  
defective function of 
lysosome  
 defective function 
of ER 
defective 




imperfecta, OI syndrome, X-linked; keratosis follicularisspinulosa decalvans, KFSD syndrome, 
X-linked) (3), they all exhibit various degrees of skeletal malformation, which are primarily 
caused by defective ER functions. By contrast, the patient in this study with a syndrome caused 





Supplemental Table 3. qPCR primers 
  
Hprt:      forward primer, 5’- CCTGCTGGATTACATCAAAGCACTG -3’ 
               reverse primer, 5’- GTCAAGGGCATATCCTACAACAAAC -3’ 
Mbtps1:  forward primer, 5’- TCCAATTGCTTGGATGACAG -3’  
                reverse primer, 5’- TCCAGAACCTTGGAGTACCG -3’  
Dhcr7:    forward primer, 5’- ACGCTGCAGGGTCTGTACTT -3’  
                reverse primer, 5’- ACAGGTCCTTCTGGTGGTTG -3’  
Sec23a:   forward primer, 5’- ACCAAAGACATGCATGGACA -3’ 
                reverse primer, 5’- CACAAACTGGATTGCACCAC -3’ 
Col1a1:   forward primer, 5’- AGCCAGCAGATCGAGAACAT -3’  
                reverse primer, 5’- TCTTGTCCTTGGGGTTCTTG -3’ 
Hspa5:    forward primer, 5’- TAGCGTATGGTGCTGCTGTC -3’ 
                reverse primer, 5’- TTTGTCAGGGGTCTTTCACC -3’ 
Ddit3:      forward primer, 5’- CAGAACCAGCAGAGGTCACA -3’ 
                    reverse primer, 5’- TCACCATTCGGTCAATCAGA -3’ 
Runx2:     forward primer, 5’- GACGAGGCAAGAGTTTCACC -3’ 
                 reverse primer, 5’- GCCTGGGGTCTGTAATCTGA -3’ 
Col2a1:    forward primer, 5’- CAGTTGGGAGTAATGCAAG -3’ 
                 reverse primer, 5’- GCCTGGATAACCTCTGTG -3’ 
Col10a1:  forward primer, 5’- AGGAATGCCTGTGTCTGCTT -3’ 
                 reverse primer, 5’- ACAGGCCTACCCAAACATGA -3’ 
Trappc2:  forward primer, 5’- GGAAGGCAGAATCCAAAGACG -3’ 
                 reverse primer, 5’- ATGCCGACACAAACCACTCG -3’ 
Mia3:       forward primer, 5’- CCTTGAGGCAGAAAGTGGAG -3’ 
                 reverse primer, 5’- CATGGGTAGCGATCTGGTTT -3’ 
Serpinh1: forward primer, 5’- AGCAGCAAGCAGCACTACAA -3’ 
                 reverse primer, 5’- AGGACCGAGTCACCATGAAG -3’ 
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Supplemental Figures 
Supplemental Figure 1. Identification of MBTPS1 compound heterozygote variants in a 
pediatric patient clinically diagnosed as mucolipidosis III and recombinant S1P expressed 
 11 
by CHO cells transfected with MBTPS1 cDNA with the maternal mutation exhibits normal 
protease activity. (A) stable complete anterolisthesis of vertebra L5 on S1 with spondylo-
epiphyseal dysplasia (I, back; II, side), gracile fibula with valgus bowing of the tibia due to 
defective endochondral ossification (III), and brachydactyly (IV). (B) Predicted catalytic domain 
of human S1P. Red, p.D365 site. Green, catalytic triad. The p.D365 is far from catalytic triad. 
(C) Western blotting of lysates from control WT CHO cells (CHO-7) and S1P-deficient CHO 
cells (SRD-12B) transfected with the indicated constructs. EGFP construct, negative control. 
ΔGPT-myc3, a construct encoding myc3-tagged GPT reporter. WT, normal non-mutated 
MBTPS1 cDNA construct with C-terminal myc-FLAG tag. SA, MBTPS1 cDNA construct with 
the catalytic-defective mutation S414A with C-terminal myc-FLAG tag. DG, MBTPS1 cDNA 
with the maternal mutation D365G with C-terminal myc-FLAG tag. Precursor and cleaved forms 
of the reporter substrate were detected in WT CHO-7 cells but not in S1P-defective CHO mutant 
SRD-12B cells. However, cleaved reporter substrate was detected in SRD-12B cells after co-
transfection with either WT or S1PD365G (DG) but not with catalytically inactive S1PS414A (SA). 
(D) DNA sequences of three forms of cloned exon 9 of the MBTPS1 cDNA expressed in patient-
derived immortalized B cells. Of the expressed transcripts, 55% are father-derived (top), 5% and 
40% are mother-derived with a missense mutation (D365G, middle) and a 41-bp deletion 
(bottom), respectively. (E) DNA sequences of exon 3 and exon 9 of MBTPS1 cDNA expressed 
in paternal or maternal immortalized B cells after treatment with the nonsense mediated mRNA 
decay (NMD) inhibitor cycloheximide for 6 hrs. Compared with expression levels in untreated 
cells, mutant transcripts are relatively increased by cycloheximide treatment, indicating that 
mutant transcripts are unstable due to the NMD quality control system.  (F) Percentage of three 
different MBTPS1 variants expression in the patient cells. Cloned patient MBTPS1 exon 9 
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cDNAs were sequenced to quantify each transcript. Given that 20% total MBTPS1 expression in 
the patient (Figure 1E), ~1% functional MBTPS1 with p.D365G is expressed in the patient. All 





Supplemental Figure 2. Patient fibroblasts do not have mucolipidosis phenotypes. (A) 
Western blotting of lysosomal proteins in lysates and culture supernatants from fibroblasts. Anti-
GAPDH, loading control. ML-II and ML-IIIa lysates or supernatants, positive controls. Unlike in 
ML-II and ML-IIIa cells, LAMP1, cathepsin B and cathepsin D were detected in lysates of 
patient cells at levels similar to those in parental cells. Excessive secretion of cathepsin D into 
the culture supernatant was not observed in patient cells. (B) Western blotting of M6P 
modification in primary fibroblast lysates (top). Incubation of the same membrane with free M6P 
as a competitive inhibitor abolishes the anti-M6P binding, confirming the specificity of anti-M6P 
scFv (bottom). (C) β-hexosaminidase activity in lysates or supernatants (top) and western 
blotting of cathepsin D in supernatant (bottom) from maternal and patient-derived fibroblasts 
treated with S1P inhibitor PF-429242 (48 hrs) as indicated. P, NH4Cl treated. Data represent 
means ± SEM; n = 34. *P < 0.0501. (D) Representative immunofluorescence images of patient-
derived fibroblasts treated with S1P inhibitor PF-429242 (48 hrs). Like ML-II and ML-IIIa cells, 
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S1P inhibitor-treated patient-derived fibroblasts displayed mucolipidosis phenotypes, indicating 
residual S1P activity is sufficient enough for patient fibroblasts to maintain proper lysosomal 
functions at least in resting states. Cathepsin D, lysosome enzyme; LAMP1, lysosome marker. 





Supplemental Figure 3. Generation of S1P-deficient and GPT-deficient (KO) cells by 
CRISPR/Cas9-mediated gene editing. (A) Targeting strategy to generate S1P-KO cells. A 
short guide RNA (sgRNA) was designed to target exon 3 of human MBTPS1. (B) Direct DNA 
sequences of edited genomes from S1P-KO clones. Clones #13 and #14 have frameshift-
mediated nonsense mutations (red arrowheads) in exon 3 of MBTPS1, resulting in gene 
disruption. (C) Targeting strategy to generate GPT-KO cells. An sgRNA was designed to target 
exon 3 of human GNPTAB. (D) Direct DNA sequences of edited genomes from GPT-KO clones. 
Clones #2, #16, and #20 have frameshift-mediated nonsense mutations (red arrowheads) in exon 
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3 of GNPTAB, resulting in gene disruption. (E) Western blotting of membrane fractions of 
different GPT-KO cell clones to validate the loss of GlcNAc-1-phosphotransferase αβ 
(αβ-precursor). Ponceau S staining was used as a loading control. The results are representative 





Supplemental Figure 4. MBTPS1fl/fl;CagCreERTM mice and MBTPS1fl/fl;Col2a1CreERT2 
mice have elevated circulating lysosomal enzymes and defective development of the 
hypertrophic chondrocyte layer of cartilage tissues. (A and B) Activities of lysosomal 
enzymes in serum were analysed from WT and various MBTPS1 mutant mice. Highly elevated 
levels of the lysosomal enzymes were detected in serum from MBTPS1 mutant mice including 
the chondrocyte-specific inducible S1P-KO mice at embryonic day 18 (E18.5) relative to WT 
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controls. Each dot represents a single mouse. Data represent means ± SD; n = 3 - 4. *P < 0.05, 
**P < 0.01. (C and D) Femur sections of WT and various MBTPS1 mutant mice (3-4 weeks of 
age) stained with haematoxylin and eosin (H&E). Res, resting chondrocyte layer; Pro, 
proliferating chondrocyte layer; Hyp, hypertrophic chondrocyte layer. Arrows indicate lack of 
hypertrophic chondrocytes. Skeletal dysplasia is caused by the disrupted growth plate where 
hypertrophic chondrocytes are lacking and therefore no longitudinal growth. Scale bar, 200 µm 
(top), 100 µm (bottom). (E) H&E-stained sections of WT and MBTPS1f/f;CagCreERTM brain (4 
weeks of age). Scale bar, 10 µm. Unlike reported GPT-deficient mice, S1P-decifient mice do not 
have inclusion body in neuronal cells, suggesting residual GPT activity in S1P-deficient neurons 




Supplemental Figure 5. Characterization of S2P-deficient patient and cells. (A) Serum 
levels of triacylglyceride, total cholesterol, high density lipoprotein (HDL) and low density 
lipoprotein (LDL) were analysed. Slightly low level of serum HDL (27 mg/dL) in the patient 
compared with in mother and her sister (57 mg/dL). (B) Targeting strategy to generate S2P-KO 
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Saos2 cells. A sgRNA was designed targeting exon 1 of human MBTPS2. (C) Direct DNA 
sequences of edited genomes from S2P-KO clones. Clones #27 and #69 have frameshift-
mediated nonsense mutations (red arrowheads) in exon 1 of MBTPS2, resulting in gene 
disruption. (D) Sequences of Exon 11 of MBTPS2 from cDNA isolated from the leukocytes of a 
S2P patient. (E) Urine N-telopeptide/Creatinine ratio, a urine biomarker for active bone matrix 
degradation mediated by collagenases. The boy patient’s mother was enrolled in this study as a 
normal control. As expected, higher N-telopepetide/Creatinine ratio was found in the S1P patient 
due to elevated secretion of collagenases but not in the S2P patient, indicating contribution of 





Supplemental Figure 6. Generation and characterization of patient and parent fibroblast-
derived iPSCs and iPSC-derived teratomas. (A) Parent and patient-derived iPSCs were 
cultured in osteogenic medium for 2 weeks, and then stained with Alizarin red S for 
mineralization during osteogenesis (left). Expression profiles of osteoblast-specific genes and ER 
stress-related genes in mother (Ma.)-derived and patient (Pa.)-derived iPSCs were analysed by 
quantitative RT-PCR after culture in osteogenic medium for 2 weeks (right). Defective 
derivation of osteoblasts from patient-iPSCs compared with maternal iPSCs. Impaired induction 
of osteoblast-lineage genes and UPR in the patient cells after osteogenic induction. Data 
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represent means ± SEM; n = 3. *P < 0.05, **P < 0.01. (B) Confocal images of 
immunofluorescence staining of Sec23a and Sec31 in the COP-II vesicles in cartilage in 
teratomas. Scale bar, 10 µm (left), 5 µm (right). As is the case with reported BBF2H7-deficient 
mice, dramatically reduced Sec23a was found in cartilages in patient teratomas compared with 
maternal cartilages, indicating impaired formation of COP-II vesicles in patient chondrocytes. 
(C) Schematic illustration of chondrocytic layers in the growth plate of a long bone. Collagen II 
is expressed in resting and proliferating chondrocytes, whereas collagen X is predominantly 
expressed in hypertrophic chondrocytes. (D) Maternal-derived and patient-derived teratomas 
were stained with antibodies against collagen II and collagen X. Arrowheads indicate densely-
stained aggregate-like structures. Scale bar, 20 µm. The results are representative of three 
independent experiments. (E) Models of defective collagen trafficking in S1P-deficient cells. 
Red dots, collagen I/II. In normal cells, accumulation of collagen in ER during development 
causes physiological ER stress and following proteolytic activation of BBF2H7 by S1P and S2P. 
Then, cytoplasmic BBF2H7 translocates into nucleus to induce gene expression of Sec23a, ER 
chaperons, mega vesicle components to release collagen in ER to extracellular space. By 
contrast, proteolytic activation of BBF2H7 is impaired in the patient, thus the patient cells are 





Supplemental Figure 7. Blocking the pathogenic splicing using AMO improves defective 
cellular functions of patient fibroblasts. (A) Summary of the DNA sequences of three forms of 
cloned exon 9 of MBTPS1 cDNA expressed in patient fibroblasts treated with AMO. Compared 
with control oligo treatment, AMO treatment increased 2-fold in correctly spliced transcript. 
Given that 10-fold increase of total MBTPS1 expression (Figure 6B, left), the absolute maternal 
transcript with a missense mutation (p.D365G) is increased 20-fold compared with control oligo-
treated cells. (B) The mRNA expression of an SREBP-regulated gene (DHCR7), collagen I 
(COL1A1), ER stress-related genes (HSPA5 and DDIT3), the secretory component (SEC23A) 
and mega vesicle components (Sedlin, Tango1 and Hsp47) were analysed by quantitative RT-
PCR after treatment with AMO. Blue, mother; red, the patient. The number indicates the fold 
change relative to time 0. Data represent means ± SEM; n = 3. *P < 0.05, **P < 0.01. 
 
